Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.
American journal of therapeutics
Source: PubMed
Summary
Emerging research shows psychedelic medicines could revolutionize mental health treatment, offering faster and more powerful relief than traditional medications. This analysis explores seven psychedelic compounds, examining their potential medical benefits and challenges. While only esketamine is currently FDA-approved for depression, these treatments show promise for various psychiatric conditions, with fewer side effects than conventional drugs.
Abstract
The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly acting treatments. It is crucial to note that this is an emerging field of medicine, and only one of these compounds (esketamine) is currently Food and Drug Administration-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.